{"id":"NCT03110562","sponsor":"Karyopharm Therapeutics Inc","briefTitle":"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma","officialTitle":"A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-24","primaryCompletion":"2020-02-18","completion":"2022-05-12","firstPosted":"2017-04-12","resultsPosted":"2021-07-08","lastUpdate":"2024-08-21"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Selinexor","otherNames":[]},{"type":"DRUG","name":"Bortezomib","otherNames":["VelcadeÂ®"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"SVd Arm: Selinexor + Bortezomib + Dexamethasone","type":"EXPERIMENTAL"},{"label":"Vd Arm: Bortezomib + Dexamethasone","type":"EXPERIMENTAL"},{"label":"SVdX Arm: Selinexor + Bortezomib + Dexamethasone","type":"EXPERIMENTAL"},{"label":"SdX Arm: Selinexor + Dexamethasone","type":"EXPERIMENTAL"}],"summary":"This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease progression per the IMWG criteria for patients in the Vd Arm.","primaryOutcome":{"measure":"SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)","timeFrame":"From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)","effectByArm":[{"arm":"SVd Arm: Selinexor + Bortezomib + Dexamethasone","deltaMin":13.93,"sd":null},{"arm":"Vd Arm: Bortezomib + Dexamethasone","deltaMin":9.46,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0075"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":157,"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Poland","Romania","Russia","Serbia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["37743180","37393120","34882831","34062004","33849608","33755235","33189178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":109,"n":195},"commonTop":["Thrombocytopenia","Neuropathy peripheral","Anaemia","Nausea","Diarrhoea"]}}